AI is transforming drug research


Generative AI is reworking drug studies and development, allowing new discoveries faster than ever — and Amgen, one of the international’s leading biotechnology groups, is tapping the technology to strength its studies.

Amgen will build AI models skilled to investigate one of the international’s biggest human datasets on an NVIDIA DGX SuperPOD, a full-stack information middle platform, with a view to be installed at Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland. The machine may be named Freyja in honor of the effective, life-giving Norse goddess associated with the capability to expect the future.

Freyja might be used to build a human diversity atlas for drug target and ailment-specific biomarker discovery, providing critical diagnostics for tracking disease progression and regression. The machine will even help increase AI-pushed precision medication fashions, doubtlessly enabling individualized treatment plans for sufferers with extreme diseases.

Amgen plans to combine the DGX SuperPOD, as a way to feature 31 NVIDIA DGX H100 nodes totaling 248 H100 Tensor Core GPUs, to train state-of-the-art AI models in days as opposed to months, enabling researchers to extra efficiently analyze and research from records of their look for novel health and therapeutics insights.

“For more than a decade, Amgen has been making ready for this hinge second we're seeing inside the enterprise, powered by way of the union of generation and biotechnology,” stated David M. Reese, executive vice president and leader era officer at Amgen. “We look ahead to  combining the breadth and maturity of our international-class human records competencies at Amgen with NVIDIA’s technology.”

The purpose of deCODE founder and CEO Kári Stefánsson in starting the agency turned into to apprehend human disease with the aid of searching at the range of the human genome. He anticipated in a latest Amgen podcast that inside the subsequent 10 years, doctors will automatically use genetics to explore uncommon sicknesses in sufferers.

“This SuperPOD has the ability to boost up our studies through education fashions more speedy and assisting us generate questions we won't have in any other case concept to invite,” said Stefánsson.

Putting the Tech in Biotechnology

Since its founding in 1996, deCODE has curated more than 200 petabytes of de-identified human information from almost 3 million people.

The organization commenced through accumulating de-recognized statistics from Icelanders, who've a rich history in genealogies that stretch returned for hundreds of years. This populace-scale records from studies volunteers provides particular insights into human variety because it applies to ailment.

DeCODE has additionally helped series more than half a million human genomes from volunteers in the UK Biobank.

But drawing insights from this plenty records calls for effective AI structures.

By integrating powerful new technology, Amgen has an possibility to accelerate the discovery and development of lifestyles-converting drug treatments. In March 2023, NVIDIA announced that Amgen have become one of the first organizations to appoint NVIDIA BioNeMo, which researchers have used to construct generative AI fashions to boost up drug discovery and development. Amgen researchers have additionally been getting access to BioNeMo thru NVIDIA DGX Cloud, an AI supercomputing carrier.

“Models educated in BioNeMo can advance drug discovery on a couple of fronts,” stated Marti Head, govt director of computational and statistics sciences at Amgen. “In addition to supporting expand drugs that are extra powerful, they can also assist keep away from undesirable results like immune responses, and new biologics may be made in quantity.”

By adopting DGX SuperPOD, Amgen is poised to gain extraordinary statistics insights with the capability to trade the tempo and scope of drug discovery.

“The fusion of advanced AI, groundbreaking tendencies in biology and molecular engineering and vast portions of human records are not simply reshaping how we find out and expand new drugs — they’re redefining remedy,” Reese stated.

Post a Comment